Plain-English translation of NCT07652905 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new immunotherapy medication, combined with three existing cancer drugs (, , and ) to treat primary plasma cell leukemia—a rare and aggressive blood cancer. All participants in this study will receive this four-drug combination to see if it helps more people achieve remission and how safe it is.
Primary plasma cell leukemia is a very serious cancer with limited treatment options. Researchers believe that this new medication, when added to standard treatments, might help patients respond better and live longer.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication combined with the other three drugs every 28 days for up to 18 treatment cycles (about 12–18 months). During this time, you'll have frequent blood tests and bone marrow exams to monitor how well the treatment is working and check for side effects. After the initial treatment cycles, you may continue on a maintenance regimen until your disease gets worse or side effects become unacceptable.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China